In August, Vaxess signed a partnership agreement with AstraZeneca to develop an RNA-based pandemic influenza prototype vaccine. Image Credit: Amanita Silvicora / Shutterstock.

With global healthcare systems experiencing a strain on resources, Vaxess Technologies is developing a messenger ribonucleic acid (mRNA) vaccine patch and raising $9m for further development.

The Vaxess MIMIX sustained release patch would allow for different infectious disease vaccines to be delivered by transdermal route. The patch consists of soluble silk fibroin microarrays filled with lipid nanoparticles of vaccines. It also has microneedles that deposit microarrays beneath the skin, these microarrays gradually dissolve over time after patch removal.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Last month, Vaxess signed a partnership agreement with AstraZeneca to develop an RNA-based pandemic influenza prototype vaccine. AstraZeneca’s vaccine pipeline drugs generated $632m in sales in H1 2023, as per the company’s Q2 financial report.

The infectious disease market is forecasted to be worth $150bn by 2029, as per GlobalData. The introduction of an alternate route of administration could increase patient ease.

GlobalData is the parent company of Pharmaceutical Technology.

Vaxess has previously reported patch stabilisation results, showing no difference in vaccine efficacy when stored at room temperatures (25°C and 37°C) compared to liquid mRNA control.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company has previously reported Phase I results from the seasonal influenza vaccine patch, VX-103. The trial compared two doses of H1N1 influenza antigen, provided by GC Biopharma, in the dermal patch.

The results showed a robust and sustained immune response, measured using seroconversion and seroprotection rates. The commonly observed adverse events included mild headache and fatigue.